United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $489.20, for a total transaction of $4,647,400.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at $158,717,515.60. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Stock Up 2.1%
Shares of NASDAQ UTHR opened at $497.97 on Wednesday. The firm has a market cap of $21.36 billion, a PE ratio of 17.82, a P/E/G ratio of 2.43 and a beta of 0.56. The company's fifty day simple moving average is $523.93 and its 200 day simple moving average is $540.20. United Therapeutics Corporation has a 12-month low of $392.17 and a 12-month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million during the quarter, compared to the consensus estimate of $804.65 million. During the same period in the previous year, the firm posted $6.41 earnings per share. The business's revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
Several institutional investors have recently bought and sold shares of the stock. Toth Financial Advisory Corp boosted its holdings in United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in shares of United Therapeutics in the second quarter valued at about $30,000. WealthCollab LLC lifted its position in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. lifted its position in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC purchased a new position in United Therapeutics during the fourth quarter worth about $31,000. Institutional investors own 94.08% of the company's stock.
Analyst Ratings Changes
A number of research analysts recently weighed in on the company. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Morgan Stanley set a $515.00 price target on shares of United Therapeutics in a research report on Thursday, August 6th. JPMorgan Chase & Co. raised their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Finally, TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $646.00.
Get Our Latest Stock Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
